Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2000
11/16/2000CA2372704A1 Use of phthalazine derivatives
11/16/2000CA2372699A1 Methods for treating tumors using antiangiogenic compounds
11/16/2000CA2372663A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2372461A1 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates
11/16/2000CA2371902A1 Novel nucleic acids and proteins with interferon-beta activity
11/16/2000CA2371469A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2370838A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000CA2369333A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000CA2369323A1 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000CA2368831A1 Permeable, water soluble, non-irritating prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/15/2000EP1052286A2 Growth hormone and growth hormone releasing hormone compositions
11/15/2000EP1051521A2 Method of screening therapeutic agents
11/15/2000EP1051511A1 Methods of identifying modulators of kinases responsive to stress
11/15/2000EP1051507A1 Antigen-specific cells, methods of generating these cells and uses thereof
11/15/2000EP1051500A2 Diagnosis and treatment of aur1 and/or aur2 related disorders
11/15/2000EP1051489A2 Compounds for therapy and diagnosis of lung cancer and methods for their use
11/15/2000EP1051486A1 Gtpase derived from human lymph nodes that effects the morphology and cytoskeleton organization of endothelial cells
11/15/2000EP1051482A1 Cytotoxic heteromeric protein combinatorial libraries
11/15/2000EP1051479A1 Novel steroid-activated nuclear receptors and uses therefor
11/15/2000EP1051421A1 Compounds containing boron for electron microscopy and for boron neutron-capture therapy
11/15/2000EP1051420A1 New cytotoxic tris(oxazole)-containing macrolides
11/15/2000EP1051407A1 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
11/15/2000EP1051403A1 Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
11/15/2000EP1051395A1 Hydroxamic and carboxylic acid derivatives
11/15/2000EP1051387A1 Anticancer platinum (iv) complexes for oral administration
11/15/2000EP1051383A1 Hydroxylation activated prodrugs
11/15/2000EP1051189A2 Vaccine formulations
11/15/2000EP1051187A1 Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
11/15/2000EP1051178A1 Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase
11/15/2000EP1051177A1 Steroid 3-o-sulphamate derivatives as inhibitors of oestrone sulphatase
11/15/2000EP1051176A1 SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
11/15/2000EP0817795B1 Novel 4-substituted-3-peptidyl-azetidin-2-one derivatives useful as cysteine proteinase inhibitor
11/15/2000EP0765343B1 MONOCLONAL ANTIBODY ACTIVE AGAINST CD44v6
11/15/2000EP0650371B1 Covalent polar lipid-peptide conjugates for biological targeting
11/15/2000CN1273580A Styryl sulfone anticancer agents
11/15/2000CN1273533A I (Robinia Pseudoacacia) lectin and its uses
11/15/2000CN1273532A Bovine excretion extracts having anticancer and anti-inflammatory activity and process for preparing the same
11/15/2000CN1273530A Method to potentiate intraveneous estramustin phosphate
11/15/2000CN1273529A Vitronection receptor antagonist
11/15/2000CN1273239A (Poly) thia acetylenic acid and it derivative, composite containing them and its application
11/15/2000CN1273113A Medicine prepared from bolostemmatoside B for preventing and curing tumor
11/15/2000CN1273100A Anticancer detoxicating pill and its preparing process
11/15/2000CN1058391C Prepared anthracene ring glucosides anticancer solution for injection
11/15/2000CN1058390C Use of compound of benzo-thiophenes
11/15/2000CN1058388C Stable freeze dried polyhematoporphyrin ether/ester composition
11/14/2000US6147255 Topical and systemic treatment of dermatological complaints associated with keratinization disorder which has effect on differentiation and on proliferation
11/14/2000US6147224 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
11/14/2000US6147223 Lactacystin analogs
11/14/2000US6147207 Bonding polyether chain ends to alcohol-reactive moieties of a porphyrin, then partially hydrogenating the porphyrin to yield a chlorin
11/14/2000US6147203 Recombinant disulfide-stabilized polypeptide fragments having binding specificity
11/14/2000US6147190 Protein associated with activating cell propagation; for the treatment of a nervous system disorders; for diagnosis and treatment of tumors; antitumor agents
11/14/2000US6147188 Irreversible cathepsin or calpain inhibitors
11/14/2000US6147187 Major histocompatibility complex proteins; for diagnosis and treatment of tumors; antitumor agents
11/14/2000US6147115 Antitumor compositions and methods of treatment
11/14/2000US6147082 Chalcones having antiproliferative activity
11/14/2000US6147080 Inhibitors of p38
11/14/2000US6147076 Analogues of N-acetylardeemin, method of preparation and uses thereof
11/14/2000US6147074 Arylsulfonylamino hydroxamic acid derivatives
11/14/2000US6147073 Substituted tetralymethylen-Oxindoles analogues as tyrosine kinase inhibitors
11/14/2000US6147061 Antiarthritic agents; anticancer agents; oral diseases
11/14/2000US6147060 Treatment of carcinomas using squalamine in combination with other anti-cancer agents
11/14/2000US6147055 Cancer treatment method utilizing plasmids suitable for IL-2 expression
11/14/2000US6146845 Polynucleotides encoding a sialoadhesin family member-2 (SAF-2)
11/14/2000US6146837 Detecting fc gamma receptor (cd64) in a biological sample by conacting sample with cyanin compound, cy5; illuminating the sample with light of an appropriate excitation wavelength; and detecting fluorescence
11/14/2000US6146829 Gapped 2' modified oligonucleotides
11/14/2000US6146659 Method of administering liposomal encapsulated taxane
11/14/2000US6146658 Prodrugs, their preparation and use as pharmaceuticals
11/14/2000US6146641 Avian leukosis virus subgroup J envelope gene product for diagnosis and immunogenic composition
11/14/2000US6146633 Endogenous and exogenous proteins, and fragments are chemically modified outside the body of an animal so that when injected into the animal, they produce more antibodies against the unmodified protein unmodified protein alone
11/14/2000US6146631 Administering a fusion protein comprising a gelonin prefered amino acid sequeance, a targeting sequence that allows internalization of fusion protein in the cell, internizing the fusion protein in the cell, eliminating the cell
11/14/2000US6146628 Biotherapeutic agents comprising recombinant PAP and PAP mutants
11/14/2000US6146624 Human ubiquitin-conjugating enzymes
11/14/2000CA2153775C Potentiation of temozolomide in human tumour cells
11/10/2000CA2307446A1 Complex for transferring an anionic substance of interest into a cell
11/09/2000WO2000066752A2 Gene construct for prodrug activation encoding a heterologous, glycosylphophati dylinositol-modified carboypeptidase g2 and a cell surface targettng signal peptide
11/09/2000WO2000066727A1 Tumour-associated antigen
11/09/2000WO2000066724A2 Oligonucleotide derivatives directed against human bcl-xl and human bcl-2 mrna
11/09/2000WO2000066632A1 Agonists or antagonists for haemopoietic growth factors
11/09/2000WO2000066631A1 SPECIFIC ANTIBODIES AND ANTIBODY FRAGMENTS FOR TGFβ¿1?
11/09/2000WO2000066630A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS
11/09/2000WO2000066618A1 Integrin receptor antagonists
11/09/2000WO2000066611A1 Steroid derivatives
11/09/2000WO2000066609A1 Oligonucleotides having a-dna form and b-dna form conformational geometry
11/09/2000WO2000066604A2 L-ribo-lna analogues
11/09/2000WO2000066593A2 Novel spirocyclic compounds, method for the production thereof and their use for treating hyperproliferative diseases
11/09/2000WO2000066591A1 Cyclocarbamate and cyclic amide derivatives
11/09/2000WO2000066590A2 Tetracyclic progesterone receptor modulator compounds and methods
11/09/2000WO2000066589A1 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
11/09/2000WO2000066587A2 Polyamines and their use in therapy
11/09/2000WO2000066584A1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV
11/09/2000WO2000066583A1 Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases
11/09/2000WO2000066581A1 Cyanopyrroles as progesterone receptor agonists
11/09/2000WO2000066576A1 Isoflavone metabolites
11/09/2000WO2000066574A1 2,1-benzisothiazoline 2,2-dioxides
11/09/2000WO2000066572A1 Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
11/09/2000WO2000066571A1 Cyclocarbamate derivatives as progesterone receptor modulators
11/09/2000WO2000066570A1 Cyclothiocarbamate derivatives as progesterone receptor modulators
11/09/2000WO2000066564A1 Benzimidazolones and analogues and their use as progesterone receptor ligands
11/09/2000WO2000066556A1 Indoline derivatives as progesterone antagonists
11/09/2000WO2000066555A1 Thio-oxindole derivatives
1 ... 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 ... 2211